Construction and Validation of a Necroptosis-Related lncRNA Signature in Prognosis and Immune Microenvironment for Glioma

Figure 8

(a) CAF, (b) Exclusion, (c) MDSC, (d)Dysfunction, (e) IFNG, (f) Merck18, (g) TAM M2, and (h) TIDE scores between two risk groups in TCGA.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)